(FM) Oncología
Departamento académico
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of Texas MD Anderson Cancer Center (62)
2024
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
Advances in Therapy
-
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Nature Communications, Vol. 15, Núm. 1
-
Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
Nature Communications , Vol. 15, Núm. 1
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer, Vol. 5, Núm. 2, pp. 347-363
2023
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Nature Communications, Vol. 14, Núm. 1
-
Genomic–transcriptomic evolution in lung cancer and metastasis
Nature, Vol. 616, Núm. 7957, pp. 543-552
-
Lung adenocarcinoma promotion by air pollutants
Nature, Vol. 616, Núm. 7955, pp. 159-167
-
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 3, pp. 323-332
-
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 525-533
-
The evolution of non-small cell lung cancer metastases in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 534-542
-
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, Vol. 616, Núm. 7957, pp. 553-562
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
European Journal of Cancer, Vol. 174, pp. S116